Momentum Biotechnologies Partners with Cube Biotech to Advance Membrane Protein Drug Discovery

• Momentum Biotechnologies and Cube Biotech have entered a strategic partnership to enhance drug discovery involving challenging membrane protein targets.

• The collaboration combines Cube Biotech’s protein technology with Momentum Biotechnologies’ mass spectrometry-based screening, aiming to accelerate the development of novel therapeutics.

Momentum Biotechnologies, a Contract Research Organization (CRO) specialising in mass spectrometry-based drug discovery, has formed a strategic partnership with Cube Biotech, a company known for its expertise in membrane protein targets.

The partnership will integrate Cube Biotech’s advanced protein technology platforms, which allow for the synthesis and purification of difficult membrane proteins while preserving their native structure, with Momentum Biotechnologies’ established mass spectrometry-based screening and characterization pipelines.

“Our premier screening capabilities provide the perfect complement to Cube’s innovative protein technologies,” said Can Ozbal, Ph.D., Founder and CEO of Momentum Biotechnologies. “This partnership will ultimately allow our clients to identify and optimise hits even more effectively, supporting the development of cutting-edge therapeutics.”

Jan Kubicek, Co-founder and CSO of Cube Biotech, added, “By combining our strengths with Momentum Biotechnologies’ offerings, we aim to break new ground in drug discovery and accelerate the development of innovative therapies.”